Collaborative Stage

Note 1: The definition of TNM in AJCC 7th Edition for tumors in corpus uteri have changed from the 6th Edition and reflects the new staging adopted by the International Federation of Gynecology and Obstetrics (FIGO). There are three schemas of FIGO Stage for cancer of the corpus uteri:
a.    Carcinoma of the endometrium and carcinosarcomas
b.    Leiomyosarcomas and endometrial stromal sarcomas (ESS)
c.    Adenosarcomas

Starting from AJCC 7th Edition and the new FIGO Edition, the above three diseases are staged separately. The table below is for leiomyosarcomas and endometrial stromal sarcomas only. When coding, pay attention to the FIGO Editions and description about cell and tumor types, disease extension, lymph node status and metastasis.
Note 2: FIGO stage is surgical, not clinical, staging.
Note 3: The AJCC 6th and 7th Editions are different for staging of this disease.
Note 4: By AJCC 7th and new FIGO Editions, positive cytology has to be reported separately (see Site Specific Factor 2), without changing stage. Since "cancer cells in ascites or in peritoneal washings" was not specifically categorized in the 1977 Summary Stage Guide, it is unclear to which stage previous cases may have been coded.
Note 5: When both FIGO Staging and extension detail are available, record the code with extension detail over the FIGO Staging. For example, in a report stating "Extension or metastasis to pelvic wall(s) or frozen pelvis, NOS (code 650) " and FIGO Stage IIB (code 675), use code 650.
Note 6: Simultaneous tumors of the uterine corpus and ovary/pelvis in association with ovarian/pelvic endometriosis should be classified as independent primary tumors.

^ For codes 100-110, 120 and 130-520 ONLY. The T category for AJCC 7th Edition staging is assigned based on the value of CS Tumor Size and CS Extension. See the extra table, CS Extension Size Table, for this schema.
* For CS Extension codes 100-400 ONLY. The SS77 and SS2000 category are assigned based on the value of CS Extension and peritoneal cytology status as coded in Site Specific Factor 2. See the extra table, CS Tumor Extension Cytology Table.

Code	Description	TNM 7 Map	TNM 6 Map	SS77 Map	SS2000 Map
000	In situ: preinvasive; noninvasive; intraepithelial Cancer in situ (see Note 3)	TX	Tis	IS	IS
100	Invasive cancer confined to corpus uteri (see Note 3)	^	T1NOS	*	*
110	Confined to endometrium (stroma)(see Note 3)	^	T1a	*	*
114	Tumor 5 cm or less in greatest dimension	T1a	T2NOS	*	*
116	FIGO Stage IA	T1a	T2NOS	*	*
120	Tumor invades less than one-half of myometrium Invasion of inner half of myometrium (see Note 3)	^	T1b	*	*
124	Tumor greater than 5 cm	T1b	T2NOS	*	*
126	FIGO Stage IB	T1b	T2NOS	*	*
130	Tumor invades one-half or more of myometrium Invasion of outer half of myometrium (see Note 3)	^	T1c	*	*
140	Invasion of myometrium, NOS	^	T1NOS	*	*
160	Tunica serosa of the visceral peritoneum (serosa covering the corpus)	^	T1NOS	*	*
400	Localized, NOS	^	T1NOS	*	*
500	Cervix uteri, NOS, but not beyond uterus (see Note 3)	^	T2NOS	RE	RE
510	Endocervical glandular involvement only (see Note 3)	^	T2a	RE	RE
520	Cervical stromal invasion (see Note 3)	^	T2b	RE	RE
530	FIGO Stage I [NOS]	T1NOS	T2NOS	RE	RE
540	Tumor limited to uterus, NOS	T1NOS	T2NOS	RE	RE
600	Adnexal involvement, NOS Extension or metastasis within true pelvis: Adnexa Fallopian tube(s) Ligaments: Broad, round, uterosacral Ovary(ies) Parametrium Pelvic serosa Tunica serosa (parietal lining of the pelvic or abdominal cavity)	T2a	T3a	RE	RE
605	FIGO Stage IIA	T2a	T3a	RE	RE
610	OBSOLETE DATA RETAINED V0200 (see Note 4 and Site Specific Factor 2) Cancer cells in ascites Cancer cells in peritoneal washings FIGO Stage IIIA	ERROR	T3a	RE	RE
620	Ureter Vulva	T2b	T3b	D	RE
640	Extension or metastasis to vagina (see Note 3)	T2b	T3b	D	RE
650	Extension or metastasis to pelvic wall(s) Described clinically as "frozen pelvis", NOS (see Note 3)	T2b	T3b	RE	RE
660	Extension or metastasis to: Bladder wall Bladder, NOS excluding mucosa Rectal wall Rectum, NOS excluding mucosa (see Note 3)	T2b	T3b	RE	RE
670	[(650) or (660)] and [(620) or (640)]	T2b	T3b	D	RE
675	FIGO Stage IIB	T2b	T3b	RE	RE
680	FIGO Stage II [NOS]	T2NOS	T3NOS	RE	RE
682	Extension beyond uterus, within pelvis, NOS	T2NOS	T3NOS	RE	RE
685	Contiguous extension to abdominal tissues, one of the following sites: Abdominal serosa (peritoneum) Cul de sac Sigmoid colon Small intestine Other abdominal tissues	T3a	T4	D	D
690	FIGO Stage IIIA	T3a	T4	D	D
692	Contiguous extension to abdominal tissues, more than one site: Abdominal serosa (peritoneum) Cul de sac Sigmoid colon Small intestine Other abdominal tissues	T3b	T4	D	D
694	FIGO Stage IIIB	T3b	T4	D	D
696	FIGO Stage III [NOS]	T3NOS	T4	D	D
698	Abdominal tissues involvement, NOS	T3NOS	T4	D	D
700	OBSOLETE DATA CONVERTED V0200 see code 710 Extension to bowel mucosa or bladder mucosa (excluding bullous edema) FIGO Stage IVA FIGO Stage IV, NOS	ERROR	ERROR	ERROR	ERROR
710	Extension to bowel mucosa or bladder mucosa (excluding bullous edema)	T4	T4	D	D
720	FIGO Stage IVA	T4	T4	D	D
730	FIGO Stage IV [NOS]	T4	T4	D	D
800	Further contiguous extension Abdominal serosa (peritoneum) Cul de sac Sigmoid colon Small intestine (see Code 685 and 692 if number of involved sites is reported)	T3NOS	T4	D	D
950	No evidence of primary tumor	T0	T0	U	U
999	Unknown extension Primary tumor cannot be assessed Not documented in patient record	TX	TX	U	U

CorpusSarcoma

CS Extension